Maraviroc Waymade

Maraviroc, the active ingredient in Maraviroc Waymade, is a CCR5 antagonist presented as an oral formulation for oral use. It treats HIV‑1 infection in adults by blocking viral entry into CD4+ cells.

GNH USA supplies Maraviroc Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maraviroc is a CCR5 antagonist used in the management of HIV‑1 infection, specifically targeting CCR5‑tropic virus strains.

- CCR5‑tropic HIV‑1 infection (treatment‑experienced): used in combination therapy to achieve viral suppression in patients who have prior antiretroviral exposure. - CCR5‑tropic HIV‑1 infection (treatment‑naïve): incorporated into initial regimens to prevent disease progression in newly diagnosed adults.

Maraviroc may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Severe liver injury - Anaphylactic reactions - QT interval prolongation - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before prescribing Maraviroc, clinicians should consider several safety measures.

- Assess CCR5 tropism: confirm virus uses CCR5 before initiating therapy. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Avoid strong CYP3A4 inducers: drugs like rifampin may reduce efficacy. - Use caution in patients with cardiovascular disease: monitor ECG for QT changes. - Pregnancy and breastfeeding: safety not established; weigh benefits against risks. - Store at room temperature: keep in original packaging, protect from moisture.

Maraviroc can interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort): may markedly decrease plasma levels. - Protease inhibitors that are potent CYP3A4 inhibitors (e.g., ritonavir): may increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole, fluconazole): may raise Maraviroc concentrations. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): may require dose adjustment. - Warfarin: monitor INR as Maraviroc can affect anticoagulant effect.